Compugen (CGEN) Expected to Release Earnings on Monday

Key Points

• Compugen is expected to report Q3 2026 results before the market opens on Monday, November 9. Analysts forecast a loss of $0.08 per share and revenue of $1.28 million; the earnings call is scheduled for 8:30 a.m. ET.
• The company exceeded expectations in its previous quarter, reporting a $0.07 per-share loss versus the estimated $0.08 loss and $2.60 million in revenue compared with the $1.28 million consensus.
• Analyst sentiment remains positive: Compugen has a consensus “Buy” rating and a $5.00 average price target, despite shares opening at $1.98 and declining 0.3%.

Compugen (NASDAQ:CGEN - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $1.28 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%. The firm had revenue of $2.60 million for the quarter, compared to the consensus estimate of $1.28 million. During the same quarter in the previous year, the business earned ($0.08) EPS. On average, analysts expect Compugen to post ($0.28) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Compugen Stock Down 0.3%

Shares of CGEN opened at $1.98 on Monday. The company has a market cap of $186.74 million, a P/E ratio of 5.21 and a beta of 2.85. Compugen has a fifty-two week low of $1.43 and a fifty-two week high of $3.23. The firm's 50 day moving average price is $2.32 and its 200 day moving average price is $2.29.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CGEN shares. HC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Compugen in a research note on Monday, October 12th. Weiss Ratings upgraded shares of Compugen from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Compugen presently has a consensus rating of "Buy" and an average target price of $5.00.

About Compugen

Compugen Ltd. NASDAQ: CGEN is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.

Compugen's research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.